You are here
HIV Vaccine Awareness Day 2010
As we mark HIV Vaccine Awareness Day on May 18, I would like to acknowledge the 16,000 volunteers in Thailand, and the hundreds of scientists, health workers, trial staff and members of the U.S. Military HIV Research Program’s team that participated in the RV144 clinical trial.
The prime boost trial in Thailand marked a ‘yes we can’ moment for the field of HIV vaccine development.
The trial demonstrated a modest ability to protect against HIV infection, reducing the number of infections by about a third. This was the first time in over two decades of research that a vaccine has shown any ability to prevent HIV infection. The result, albeit a modest one, is a significant scientific milestone that we can build upon for future, more effective HIV vaccines.
We hope to use data from RV144 to determine the specific immune responses the body needs to protect itself from HIV. The results of the RV144 trial have already prompted scientists to rethink how they approach and test a vaccine to protect against HIV. Our program is collaborating with researchers around the globe to dissect the results from this trial to inform basic research and design future clinical trials to translate a scientific milestone into an eventual public health tool.
Thirty years ago, the World Health Organization declared that smallpox— one of the most devastating diseases in human history— had been eradicated after an intense surveillance and global vaccination campaign. It is my hope that the similar statement can one day be made about HIV, which is currently the second largest infectious disease killer in the world.
HIV has taken the lives of nearly 27 million people, and it is estimated that more than 33 million people were living with HIV at the end of 2008. It poses a great threat to public health and stability in countries where it is prevalent. This disease must be stopped, and as history has shown us, an effective vaccine is the ultimate solution to control a pandemic.